Daniel Woodsworth
M.D./Ph.D Program
Previous Degree: B.Sc. Physics
2011 Cohort
Cytotoxic T-lymphocytes (CTLs) have two key features that make them potential therapeutic devices. First, due to their T-cell receptors (TCRs), CTLs are able to precisely target specific cells displaying tumor or viral antigens. Second, having recognized a harmful cell, CTLs are endowed with a host of effector mechanisms that enable them to rapidly induce target cell death (apoptosis). These properties are exploited in the field of adoptive cell therapy (ACT), where CTLs specific for a tumor antigen are administered to cancer patients. My research aims to improve and expand the range of therapies that can be delivered with engineered CTLs.
Supervisor: Robert Holt
